Wenying Yang

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 25

Top Topics

Insulin Resistance

Metabolic Syndrome

Top Venues

Diabetes, obesity & metabolism

Journal of diabetes

Nature medicine

Diabetes/metabolism research and reviews

This page only lists publications with an associated author ORCID identifier.

Publications

Yao Wang, Chengxia Jiang, Xiaolin Dong, Mingwei Chen, Qin Gu, Lihui Zhang, Yanqin Fu, Tianrong Pan, Yan Bi, Weihong Song, Jing Xu, WeiPing Lu, Xiaodong Sun, Zi Ye, Danli Zhang, Liang Peng, Xiang Lin, Wei Dai, Quanren Wang, Wenying Yang
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes, obesity & metabolism 26 (7) (2024)
Yao Wang, Chengxia Jiang, Xiaolin Dong, Mingwei Chen, Qin Gu, Lihui Zhang, Yanqin Fu, Tianrong Pan, Yan Bi, Weihong Song, Jing Xu, WeiPing Lu, Xiaodong Sun, Zi Ye, Danli Zhang, Liang Peng, Xiang Lin, Wei Dai, Quanren Wang, Wenying Yang
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes, obesity & metabolism (2024)
Yao Wang, Chengxia Jiang, Xiaolin Dong, Mingwei Chen, Qin Gu, Lihui Zhang, Yanqin Fu, Tianrong Pan, Yan Bi, Weihong Song, Jing Xu, WeiPing Lu, Xiaodong Sun, Zi Ye, Danli Zhang, Liang Peng, Xiang Lin, Wei Dai, Quanren Wang, Wenying Yang
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes, obesity & metabolism 26 (7) (2024)
Wenying Yang, Xiaohui Guo, Felipe Lauand, Lingyu Li, Hexin Fang, Qin Du, Lei Kang
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials. Diabetes, obesity & metabolism 26 (4) (2024)
Wenying Yang, Xiaohui Guo, Felipe Lauand, Lingyu Li, Hexin Fang, Qin Du, Lei Kang
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials. Diabetes, obesity & metabolism 26 (4) (2024)
Wenying Yang, Xiaohui Guo, Felipe Lauand, Lingyu Li, Hexin Fang, Qin Du, Lei Kang
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials. Diabetes, obesity & metabolism (2024)
Wenying Yang, Xiaohui Guo, Felipe Lauand, Lingyu Li, Hexin Fang, Qin Du, Lei Kang
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials. Diabetes, obesity & metabolism 26 (4) (2024)
Xiaohui Guo, Wenying Yang, Junqing Zhang, Xiaolin Dong, Ming Liu, Shenghong Gu, Felipe Lauand, Lingyu Li, Qiong Huang, Lei Kang, Elisabeth Souhami
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism (2023)
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Ziling Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang
Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study. Journal of diabetes 14 (12) (2022)
Wenying Yang, Xiaolin Dong, Qingju Li, Zhifeng Cheng, Guoyue Yuan, Ming Liu, Jianzhong Xiao, Shenghong Gu, Elisabeth Niemoeller, Lijuan Chen, Lin Ping, Elisabeth Souhami, null null
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Diabetes, obesity & metabolism 24 (8) (2022)
Wenying Yang, Da-Long Zhu, Shenglian Gan, Xiaolin Dong, Junping Su, Wenhui Li, Hongwei Jiang, Wenjuan Zhao, Minxiu Yao, Weihong Song, Yibing Lu, Xiuzhen Zhang, Huifang Li, Guixia Wang, Wei Qiu, Guoyue Yuan, Jianhua Ma, Wei Li, Ziling Li, Xiaoyue Wang, Jiao'e Zeng, Zhou Yang, Jingdong Liu, Yongqian Liang, Song Lu, Huili Zhang, Hui Liu, Ping Liu, Kuanlu Fan, Xiaozhen Jiang, Yufeng Li, Qing Su, Tao Ning, Huiwen Tan, Zhenmei An, Zhaoshun Jiang, Lijun Liu, Zunhai Zhou, Qiu Zhang, Xuefeng Li, Zhongyan Shan, Yaoming Xue, Hong Mao, Lixin Shi, Shandong Ye, Xiaomei Zhang, Jiao Sun, Ping Li, Yang Tao, Feng Li, Jingna Lin, Zhinong Zhang, Ying Zhao, Ruonan Li, Xiaohui Guo, Qi Yao, Weiping Lu, Shen Qu, Hongmei Li, Liling Tan, Wenbo Wang, Yongli Yao, Daoxiong Chen, Yulan Li, Jialin Gao, Wen Hu, Xiaoqiang Fei, Tianfeng Wu, Song Dong, Wenlong Jin, Chenzhong Li, Dong Zhao, Bo Feng, Yu Zhao, Yi Zhang, Xiaoying Li, Fuxing Tang
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine 28 (5) (2022)
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Ziling Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang
Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study. Journal of diabetes 14 (12) (2022)
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Ziling Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang
Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study. Journal of diabetes 14 (12) (2022)
Wenying Yang, Shahid Akhtar, Edward Franek, Martin Haluzík, Takahisa Hirose, Balamurali Kalyanam, Soumitra Kar, Ted Wu, Dilek Gogas Yavuz, Ambika Gopalakrishnan Unnikrishnan
Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes therapy : research, treatment and education of diabetes and related disorders 13 (2) (2022)
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Ziling Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang
Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study. Journal of diabetes 14 (12) (2022)
Xiaoping Chen, Hongwei Jiang, Hongmei Li, Hongyu Kuang, Li Chen, Jianhua Ma, Qiu Zhang, Tianrong Pan, Wenying Yang, null null
Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS). Diabetes, obesity & metabolism (2022)
Hongwei Jiang, Shuguang Pang, Yawei Zhang, Ting Yu, Meng Liu, Huan Deng, Li Li, Liqi Feng, Baili Song, Han Han-Zhang, Qingyang Ma, Lei Qian, Wenying Yang
A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature communications 13 (1) (2022)
Da-Long Zhu, Xiaoying Li, Jianhua Ma, Jiao'e Zeng, Shenglian Gan, Xiaolin Dong, Jing Yang, Xiaohong Lin, Hanqing Cai, Weihong Song, Xuefeng Li, Keqin Zhang, Qiu Zhang, Yibing Lu, Ruifang Bu, Huige Shao, Guixia Wang, Guoyue Yuan, Xingwu Ran, Lin Liao, Wenjuan Zhao, Ping Li, Li Sun, Lixin Shi, Zhaoshun Jiang, Yaoming Xue, Hongwei Jiang, Quanmin Li, Zongbao Li, Maoxiong Fu, Zerong Liang, Lian Guo, Ming Liu, Chun Xu, Wenhui Li, Xuefeng Yu, Guijun Qin, Zhou Yang, Benli Su, Longyi Zeng, Houfa Geng, Yongquan Shi, Yu Zhao, Yi Zhang, Wenying Yang, Fuxing Tang
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine 28 (5) (2022)
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Ziling Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang
Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study. Journal of diabetes (2022)
Haiqing Zhu, Xiaoping Chen, Bo Zhang, Wenying Yang, Xiaoyan Xing
Family History of Diabetes and the Effectiveness of Lifestyle Intervention on Insulin Secretion and Insulin Resistance in Chinese Individuals with Metabolic Syndrome. Journal of diabetes research 2021 (2021)
Xiaomu Kong, Zhaojun Yang, Bo Zhang, Xiaoping Chen, Liping Yu, Haiqing Zhu, Xiaoyan Xing, Wenying Yang
Maternal and paternal histories differentially influence risks for diabetes, insulin secretion and insulin resistance in a Chinese population. Journal of diabetes investigation 12 (3) (2020)
Wenying Yang, Xiangjin Xu, Tao Lei, Jianhua Ma, Ling Li, Jie Shen, Binqi Ye, Sandy Zhu, Thomas Meinicke
Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism 23 (2) (2020)
Wenying Yang, Jianhua Ma, Tianpei Hong, Ming Liu, Heng Miao, Yongde Peng, Changjiang Wang, Xiangjin Xu, Tao Yang, Anne Møller Nielsen, Lili Pan, Weihong Liu, Weigang Zhao
Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial. Diabetes, obesity & metabolism 21 (7) (2019)
Wenying Yang, Jianhua Ma, Guoyue Yuan, Ling Li, Min Zhang, Yibing Lu, Xinhua Ye, Weihong Song, Ming Liu, Jun Wu, Riqiu Chen, Yunguang Li, Xia Zhang, Nan Cui, Jinkui Yang
Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial. Diabetes, obesity & metabolism 21 (8) (2019)
Xiaomu Kong, Xiaoyan Xing, Xuelian Zhang, Jing Hong, Wenying Yang
Early-onset type 2 diabetes is associated with genetic variants of β-cell function in the Chinese Han population. Diabetes/metabolism research and reviews 36 (2) (2019)